NCT00584974View on ClinicalTrials.gov

A Safety, Efficacy and Tolerability Study of SEP-225289

PHASE2CompletedINTERVENTIONAL
Enrollment

523

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Depressive Disorder, Major
Interventions
DRUG

SEP-225289

0.5 mg SEP-225289

DRUG

SEP-225289

2.0 mg SEP-225289

DRUG

Venlafaxine

150 mg Venlafaxine

DRUG

placebo

Placebo

Trial Locations (51)

10021

New York

10023

New York

10075

New York

10454

The Bronx

10467

The Bronx

11235

Brooklyn

19149

Philadelphia

23112

Midlothian

27609

Raleigh

30080

Smyrna

30328

Atlanta

30341

Atlanta

32216

Jacksonville

32751

Maitland

32771

Sanford

33139

Lauderhill

33161

North Miami

33912

Fort Myers

34208

Bradenton

39232

Flowood

44130

Middleburg Heights

45227

Cincinnati

45408

Dayton

60068

Park Ridge

63301

Saint Charles

70601

Lake Charles

72211

Little Rock

73112

Oklahoma City

75062

Irving

75231

Dallas

77040

Houston

78756

Austin

80204

Denver

80239

Denver

87109

Albuquerque

90210

Beverly Hills

91007

Arcadia

91204

Glendale

91786

Upland

92056

Oceanside

92103

San Diego

92618

Irvine

92626

Costa Mesa

92845

Garden Grove

94549

Lafayette

97210

Portland

98104

Seattle

06050

New Britain

02135

Boston

02184

Braintree

08021

Clementon

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00584974 - A Safety, Efficacy and Tolerability Study of SEP-225289 | Biotech Hunter | Biotech Hunter